OPKO Health (OPK) Plans Presentation of hGH-CTP Phase 2 Continuation Data at Upcoming Conference
Tweet Send to a Friend
OPKO Health, Inc. (NYSE: OPK) announced it will present 18-24 month clinical data from its ongoing open label extension study ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
